Company: KROS
Filing Date: 2025-05-19
Form Type: DEFA14A
Source: 0001104659-25-050245
Chunk: 8

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-19
Form: DEFA14A
Chunk 8
---
 and Management."
To the extent that the Company's directors and executive officers have acquired or disposed of securities holdings since the applicable
"as of" date disclosed in the Proxy Statement, such transactions have been or will be reflected on Statements of Changes in
Ownership of Securities on Form 4 or Initial Statements of Beneficial Ownership of Securities on Form 3 filed with the SEC. These documents
are or will be available free of charge at the SEC’s website at www.sec.gov.

Contacts

Investor Contact:

Justin Frantz

jfrantz@kerostx.com

617-221-6042

Media Contact:

Mahmoud Siddig / Adam Pollack / Viveca Tress

Joele Frank, Wilkinson Brimmer Katcher

(212) 355-4449